Get started
Author

Matthias Bischof

Observed names: Bischof, Matthias, M Bischof
ORCID: 0009-0007-8697-8614
Observed ORCID: 0009-0007-8697-8614
OpenAlex ID: A5019374422
Cost-utility analysis of newborn screening for spinal muscular atrophy in Japan
2024 · Akira Hata, Akihito Uda, et al. · Journal of Medical Economics · 8
Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands
2025 · Simon van der Schans, Rimma Velikanova, et al. · The European Journal of Health Economics · 4
PDF
EE121 Economic Consequences of Persistence and Adherence to Lifelong Therapy for Patients with Presymptomatic Spinal Muscular Atrophy (SMA)
2024 · J Kleintjens, A Patel, et al. · Value in Health · 1
PCR145 Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy (SMA) in Italy
2022 · G Ghetti, FS Mennini, et al. · Value in Health · 1
PDF
EE424 Societal Costs of Spinal Muscular Atrophy Type 1 for Patients Treated with Onasemnogene Abeparvovec or Nusinersen in the United Kingdom
2024 · J Kleintjens, A Patel, et al. · Value in Health
PDF
EE471 Cost Effectiveness of Newborn Screening (NBS) for Spinal Muscular Atrophy (SMA) in England
2022 · D Weidlich, L Servais, et al. · Value in Health
Works count: 7
Citation count: 14
H-index: 2
I10-index:
Year
Topic
Type